Evidence map›Paper›PMID 41121376›Full record

ArticleCell communication and signaling : CCS2025

Phenotype switching in highly invasive resistant to vemurafenib and cobimetinib melanoma cells.

Aleksandra Simiczyjew, Magdalena Kot, Michał Majkowski, Marcin Ziętek, Rafał Matkowski, Dorota Nowak

Abstract read
In one paragraph

Article in Cell communication and signaling : CCS, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Aleksandra SimiczyjewDepartment of Cell Pathology, Faculty of Biotechnology, University of Wroclaw, Joliot-Curie 14a, Wroclaw, 50-383, Poland. aleksandra.simiczyjew@uwr.edu.pl.
Magdalena KotDepartment of Cell Pathology, Faculty of Biotechnology, University of Wroclaw, Joliot-Curie 14a, Wroclaw, 50-383, Poland.
Michał MajkowskiDepartment of Cell Pathology, Faculty of Biotechnology, University of Wroclaw, Joliot-Curie 14a, Wroclaw, 50-383, Poland.
Marcin ZiętekDepartment of Oncology, Division of Surgical Oncology, Wroclaw Medical University, Plac Hirszfelda 12, Wroclaw, 53-413, Poland.
Rafał MatkowskiDepartment of Oncology, Division of Surgical Oncology, Wroclaw Medical University, Plac Hirszfelda 12, Wroclaw, 53-413, Poland.
Dorota NowakDepartment of Cell Pathology, Faculty of Biotechnology, University of Wroclaw, Joliot-Curie 14a, Wroclaw, 50-383, Poland.

Funding

National Science Centre, Poland 2020/39/D/NZ5/02330
6 · The paper itself

Abstract

backgroundA mutation in the BRAF (serine/threonine-protein kinase B-raf) gene is most often responsible for the progression of melanoma. A breakthrough in its treatment was the application of BRAF and MEK (mitogen-activated protein kinase kinase) inhibitors. Unfortunately, the effectiveness of this therapy is limited due to rapidly emerging resistance to the drugs. We derived two melanoma cell lines resistant to vemurafenib (a BRAF inhibitor)/cobimetinib (an MEK inhibitor). Due to the significant impact of invasion on cancer progression, we focused our further research on this process.

methodsCell migration and invasion were assessed via the scratch wound assay. Selected proteins' level as well as the activation of focal adhesion kinase (FAK) were evaluated using Western blotting. The expression of the selected genes was examined by qRT-PCR. The focal adhesions parameters, actin polymerization ratio, as well as YAP/TAZ (Yes-associated protein/transcriptional co-activator with PDZ-binding motif), invadopodia, and β and γ actin localization were analyzed using confocal microscopy. The composition and activity of proteases secreted by cells were determined using a human protease array and gelatin zymography. In addition, cell adhesion and matrix metalloproteinase (MMP14) activity were assessed using appropriate assays.

resultsOur analysis showed a greater capacity for migration and invasion of resistant melanoma cells compared to controls, as well as an increase in the level of RUNX2 (runt-related transcription factor 2). Moreover, examined cells exhibited higher adhesion to the surface and were more spread. These cells also formed more focal adhesions. Furthermore, we noticed an increased level of α-parvin and vinculin in resistant cells, as well as an elevated activation of FAK (focal adhesion kinase). Resistance was additionally accompanied by rearrangement of the actin cytoskeleton. Examined cells formed more stress fibers compared to control cells. YAP/TAZ localization became much more nuclear in the resistant ones. The amount of invadopodia was increased, which was reflected by elevated secretion and activation of proteases, as well as altered expression of their inhibitors.

conclusionsIn summary, our study characterized a significantly more invasive phenotype of double-resistant cell lines compared to melanoma cells sensitive to BRAF and MEK inhibitors. Successful inhibition of this phenotype could result in more effective therapy and thus a better prognosis for patients.

Indexed as

AzetidinesDrug Resistance, NeoplasmIndolesMelanomaPiperidinesSulfonamidesVemurafenibActinsCell Line, TumorCell MovementFocal AdhesionsHumansNeoplasm InvasivenessPhenotypeActinsAzetidinescobimetinibIndolesPiperidinesSulfonamidesVemurafenibBRAF inhibitorCobimetinibDrug resistanceMEK inhibitorMelanomaVemurafenib

Identifiers

PMID41121376
PMCPMC12542628

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.